Ono Pharmaceutical Company Selects Medidata Rave as Enterprise EDC/CDM Solution

Ono Pharmaceutical Company Selects Medidata Rave as Enterprise EDC/CDM Solution

January 18, 2012

Standard Use of Rave by Japanese Specialty Pharma Across All Trials Will Streamline Research, Accelerate Decision Making and Help Expand Global Network

NEW YORK & OSAKA, Japan--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced Japanese-based Ono Pharmaceutical Co., Ltd. has selected Medidata Rave® as its electronic data capture (EDC) and clinical data management (CDM) solution. The innovation-focused Ono will use Rave as a first preference for all clinical trials in Japan.

Specializing in Phase II and III clinical trials in oncology, carpal tunnel syndrome, diabetes and other therapeutic areas, Ono was impressed with Rave's ability to improve operational efficiency and enhance workflow throughout the clinical trial process. Beyond functional requirements, Ono also selected Medidata for its strong global presence and reputation for dependability as the company seeks to develop candidate compounds for new drugs and actively conduct trials outside of Japan. During the evaluation phase, Ono deployed Rave in trials across several therapeutic areas and valued the system's advantages.

"Not only does Rave deliver most of the functionality we were seeking in an EDC solution, but Medidata's strong global footprint - especially in Japan - offers us an unmatched resource in the industry," said Satoru Fukinbara, Ph.D., director of data science at Ono's development headquarters. "Medidata's established network of satisfied and successful sponsors, in addition to a strong support team, gives us access to a wealth of knowledge and best practices that can help guide our efforts in our global expansion."

Ono is examining its standardization process using EDC and anticipates immediate benefits for both site users and sponsors, particularly real-time access to clinical data. Ono has already participated in the Japan Medidata User Group (J-MUG), a collaborative forum of more than 40 companies in which Medidata customers share knowledge, experiences and best practices, and plans to actively participate in the 2012 J-MUG.

"Ono is one of Japan's leading specialty pharmaceutical companies, and we're excited to play a role in helping them drive continued innovation," said Tarek Sherif, CEO, Medidata Solutions. "Our leadership in clinical research in the Asia-Pacific region and broad global network enhance our ability to help Ono achieve its goal of streamlining trials and strengthening global alliances."

About Ono Pharmaceutical Co., Ltd.

In keeping with its philosophy of "Dedicated to Man's Fight against Disease and Pain" Ono Pharmaceutical Co. Ltd. has always strived to achieve its goal of serving as an R&D-oriented global specialty pharmaceuticals, aiming to develop innovative and globally recognized drugs. To do this, Ono has been engaged in drug discovery research based on accumulated technologies and know-how in areas where Ono's strengths can be fully exploited (i.e. bioactive lipid agonists and enzyme inhibitors such as proteases and kinases). In addition, modulators of membrane transport system such as ion-channels and transporters as well as biotechnology based medicines are also the areas of our focus where we drive forward our research effectively deploying our research know-how together with the latest information acquired from global research institutions on drug discovery targets and the cutting-edge drug discovery technologies that biopharmaceutical companies can offer. For additional information please go to www.ono.co.jp.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics. Connect with Medidata online by following us on Twitter (@Medidata) or visiting us on LinkedIn.

Contacts

Lois Paul & Partners
Susan McCarron, 617-986-5767
[email protected]

 

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.